Limits...
Professor Viraj A. Master: surgery is a single "strike".

Zhou S - Transl Androl Urol (2016)

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Master’s primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers... The other one is that the discussion is great... Because you can hear a person who does not normally deal with urological cancers talking about his opinions on the data, and you can have someone who doesn’t know much about stone disease but he could ask a good question... In general aspect, the tremendous understanding of prostate cancer biology, particularly stratifying patients into those who need treatment, versus those who may be well served with surveillance only, could be considered truly significant progress in urological surgery... Meaning, certain urological patients with prostate cancer can be followed and the data is kept coming out... Also, I think the continuing use of minimal invasive surgery is really important, which is highlighted by the use of robotic surgery for prostate cancer... As a worldwide community, we can do minimal invasive surgeries for those patients with penile cancer while developed in South America, many groups like ours, others in Europe and in Asia, for example in Fudan, China... Minimal invasive surgery is a revolutionary technique that has transformed surgery of the groin for malignancy... Solid anatomical knowledge are very good teachers, which would be a key factor to performing successful urological surgery... Anatomy in the modern years has become forgotten by many young surgeons, as they will often look at journal articles... I suggest that the young surgeons should concentrate on fundamental knowledge of anatomy as a foundational skill, and then build upon this knowledge... We focus on advanced kidney cancer and immunology... Common cost-effective, serum biomarkers are available worldwide, such as in China, India, US and Europe... Multiple groups across the world are doing amazing research in pursuing serum markers to predict outcome, but a large fraction of them will do the expensive tests, usually in the research setting... We are working on in collaborating with other groups to try and prove that ‘simpler’ blood tests can provide meaningful information on outcome.

No MeSH data available.


Professor Viraj A. Master.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4837305&req=5

f1: Professor Viraj A. Master.

Mentions: Prof. Viraj A. Master (Figure 1) is a Professor of Urology at the Emory University School of Medicine, the director of Clinical Research Unit and the associate chair for Clinical Affairs and Quality. Prof. Master’s primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers. Prof. Master has lectured both nationally and internationally, as well as authored multiple book chapters and over 150 peer-reviewed scientific journal articles. He also is closely involved in teaching and mentoring medical students, urology residents and post-graduate fellows.


Professor Viraj A. Master: surgery is a single "strike".

Zhou S - Transl Androl Urol (2016)

Professor Viraj A. Master.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4837305&req=5

f1: Professor Viraj A. Master.
Mentions: Prof. Viraj A. Master (Figure 1) is a Professor of Urology at the Emory University School of Medicine, the director of Clinical Research Unit and the associate chair for Clinical Affairs and Quality. Prof. Master’s primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers. Prof. Master has lectured both nationally and internationally, as well as authored multiple book chapters and over 150 peer-reviewed scientific journal articles. He also is closely involved in teaching and mentoring medical students, urology residents and post-graduate fellows.

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Master’s primary clinical interest is urologic oncology, in particular kidney cancer, adrenal tumors, testicular cancer, high-risk prostate cancer and penile cancers... The other one is that the discussion is great... Because you can hear a person who does not normally deal with urological cancers talking about his opinions on the data, and you can have someone who doesn’t know much about stone disease but he could ask a good question... In general aspect, the tremendous understanding of prostate cancer biology, particularly stratifying patients into those who need treatment, versus those who may be well served with surveillance only, could be considered truly significant progress in urological surgery... Meaning, certain urological patients with prostate cancer can be followed and the data is kept coming out... Also, I think the continuing use of minimal invasive surgery is really important, which is highlighted by the use of robotic surgery for prostate cancer... As a worldwide community, we can do minimal invasive surgeries for those patients with penile cancer while developed in South America, many groups like ours, others in Europe and in Asia, for example in Fudan, China... Minimal invasive surgery is a revolutionary technique that has transformed surgery of the groin for malignancy... Solid anatomical knowledge are very good teachers, which would be a key factor to performing successful urological surgery... Anatomy in the modern years has become forgotten by many young surgeons, as they will often look at journal articles... I suggest that the young surgeons should concentrate on fundamental knowledge of anatomy as a foundational skill, and then build upon this knowledge... We focus on advanced kidney cancer and immunology... Common cost-effective, serum biomarkers are available worldwide, such as in China, India, US and Europe... Multiple groups across the world are doing amazing research in pursuing serum markers to predict outcome, but a large fraction of them will do the expensive tests, usually in the research setting... We are working on in collaborating with other groups to try and prove that ‘simpler’ blood tests can provide meaningful information on outcome.

No MeSH data available.